There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Marinus (MRNS – Research Report), uniQure (QURE – Research Report) and eFFECTOR Therapeutics (EFTR – Research Report) with bullish sentiments.
Marinus (MRNS)
RBC Capital analyst Brian Abrahams maintained a Buy rating on Marinus on April 4 and set a price target of $24.00. The company’s shares closed last Monday at $8.20.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
Marinus has an analyst consensus of Strong Buy, with a price target consensus of $19.78, implying a 152.0% upside from current levels. In a report issued on March 24, Jefferies also maintained a Buy rating on the stock with a $22.00 price target.
See the top stocks recommended by analysts >>
uniQure (QURE)
In a report issued on April 4, Luca Issi from RBC Capital maintained a Buy rating on uniQure, with a price target of $23.00. The company’s shares closed last Monday at $5.20, close to its 52-week low of $4.76.
According to TipRanks.com, Issi ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on uniQure is a Moderate Buy with an average price target of $18.86, which is a 264.8% upside from current levels. In a report issued on April 2, UBS also maintained a Buy rating on the stock with a $27.00 price target.
eFFECTOR Therapeutics (EFTR)
In a report released yesterday, Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on eFFECTOR Therapeutics, with a price target of $10.00. The company’s shares closed last Monday at $2.13.
According to TipRanks.com, Burnett ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
eFFECTOR Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.67, a 296.3% upside from current levels. In a report issued on March 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $24.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRNS:
